A detailed history of Advisor Group Holdings, Inc. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 75 shares of MLTX stock, worth $3,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75
Previous 100 25.0%
Holding current value
$3,600
Previous $5,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$38.43 - $48.6 $960 - $1,215
-25 Reduced 25.0%
75 $3,000
Q1 2024

May 10, 2024

SELL
$43.78 - $63.86 $83,926 - $122,419
-1,917 Reduced 95.04%
100 $5,000
Q4 2023

Feb 12, 2024

BUY
$36.35 - $63.02 $25,735 - $44,618
708 Added 54.09%
2,017 $121,000
Q3 2023

Nov 13, 2023

BUY
$48.35 - $61.26 $24,465 - $30,997
506 Added 63.01%
1,309 $74,000
Q2 2023

Aug 10, 2023

BUY
$19.01 - $51.79 $13,820 - $37,651
727 Added 956.58%
803 $40,000
Q1 2023

May 12, 2023

BUY
$11.03 - $23.7 $838 - $1,801
76 New
76 $1,000

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.77B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.